Related Experiment Video
Updated: Jun 3, 2026
11:15
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Adenosquamous lung carcinomas: a histologic subtype with poor prognosis.
Pier Luigi Filosso1, Enrico Ruffini, Sofia Asioli
1University of Torino Italy, Department of Thoracic Surgery, Via Genova, 3 10126 Torino, Italy. pierluigi.filosso@unito.it
Lung Cancer (Amsterdam, Netherlands)
|March 5, 2011
Summary
Adenosquamous (ADS) lung cancer is aggressive with poor survival rates compared to adenocarcinoma (AD) and squamous cell carcinoma (SCC). Adjuvant chemotherapy improves survival, even in early-stage ADS.
Area of Science:
- Thoracic Oncology
- Surgical Pathology
- Cancer Research
Background:
- Adenosquamous carcinoma (ADS) of the lung is a rare subtype.
- Prognostic factors and outcomes for ADS require further investigation.
- Comparison with adenocarcinoma (AD) and squamous cell carcinoma (SCC) is essential.
Purpose of the Study:
- To evaluate prognostic factors and outcomes in patients undergoing surgery for lung adenosquamous carcinoma (ADS).
- To compare the prognosis of ADS with lung adenocarcinoma (AD) and squamous cell carcinoma (SCC).
Main Methods:
- Retrospective review of a thoracic cancer surgical database.
- Inclusion of patients with ADS, SCC, and AD operated between January 1995 and December 2009.
- Analysis of survival rates, recurrence patterns, and prognostic factors.
Main Results:
- Adenosquamous carcinoma (ADS) presented at a higher stage with worse overall survival than AD or SCC.
- Three and 5-year survival rates for ADS were 25% and 15%, respectively.
- Distant metastases (MTS), particularly brain MTS, and local recurrences were common; adjuvant chemotherapy significantly improved survival.
Conclusions:
- Adenosquamous carcinoma (ADS) lung tumors are aggressive and uncommon.
- Adjuvant chemotherapy is recommended for all radically resected ADS, including Stage I.
- Prophylactic whole-brain radiotherapy may reduce the risk of brain metastases.